{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:43:08Z","timestamp":1792395788573,"version":"4.4.0"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation of the target protein is emerging as a promising modality for the development of therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, and the capacity to selectively target \u201cundruggable\u201d proteins. This marks a revolutionary advancement in the landscape of small molecule drugs. Given that molecular glue research is still in its early stage, we summarized the mechanisms of molecular glue, the promising drugs in clinical trials and diverse feasible design strategies for molecular glue therapeutics.<\/jats:p>","DOI":"10.3389\/fonc.2024.1512666","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:12:31Z","timestamp":1733980351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular glue degrader for tumor treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Yuhan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quande","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao5902","article-title":"Chemically induced proximity in biology and medicine","volume":"359","author":"Stanton","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00449","article-title":"Molecular glue discovery: current and future approaches","volume":"66","author":"Dewey","year":"2023","journal-title":"J Med Chem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1039\/D2CB00207H","article-title":"Protein-protein interfaces in molecular glue-induced ternary complexes: classification, characterization, and prediction","volume":"4","author":"Rui","year":"2023","journal-title":"RSC Chem Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: the tragedy of birth defects and the effective treatment of disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.035","article-title":"The role of thalidomide in multiple myeloma","volume":"7","author":"Schwab","year":"2006","journal-title":"Clin Lymphoma Myelom"},{"key":"B7","first-page":"490","article-title":"Thalidomide celgene corp","volume":"1","author":"Bruyn","year":"1998","journal-title":"Idrugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Ito","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-2867(97)80028-X","article-title":"Cyclosporine and tacrolimus","volume":"12","author":"Vaden","year":"1997","journal-title":"Semin Vet Med Surg Small Anim"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645080-00002","article-title":"Chronopharmacokinetics of ciclosporin and tacrolimus","volume":"45","author":"Baraldo","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2021.04.009","article-title":"Haven\u2019t got a glue: Protein surface variation for the design of molecular glue degraders","volume":"28","author":"Kozicka","year":"2021","journal-title":"Cell Chem Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0594-x","article-title":"Rational discovery of molecular glue degraders via scalable chemical profiling","volume":"16","author":"Mayor-Ruiz","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.2c00245","article-title":"Molecular glues: the adhesive connecting targeted protein degradation to the clinic","volume":"62","author":"Sasso","year":"2023","journal-title":"Biochemistry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature05175","article-title":"Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery","volume":"443","author":"Angers","year":"2006","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322412111","article-title":"E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells","volume":"111","author":"Samant","year":"2014","journal-title":"P Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11010-014-1960-3","article-title":"E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation","volume":"390","author":"Thirunavukarasou","year":"2014","journal-title":"Mol Cell Biochem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000049","article-title":"Regulation of blood pressure and renal electrolyte balance by Cullin-RING ligases","volume":"23","author":"Uchida","year":"2014","journal-title":"Curr Opin Nephrol Hy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1483206","article-title":"DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases","volume":"20","author":"He","year":"2006","journal-title":"Genes Dev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.08.010","article-title":"A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1","volume":"23","author":"Jin","year":"2006","journal-title":"Mol Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1490","article-title":"CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation","volume":"8","author":"Higa","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.574210","article-title":"CRL4Cdt2 E3 ubiquitin ligase and proliferating cell nuclear antigen (PCNA) cooperate to degrade thymine DNA glycosylase in S phase","volume":"289","author":"Shibata","year":"2014","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.553388","article-title":"DNA damage induces the accumulation of Tiam1 by blocking \u03b2-TrCP-dependent degradation","volume":"289","author":"Zhu","year":"2014","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.2003.01159.x","article-title":"Ikaros, Aiolos and Helios: transcription regulators and lymphoid Malignancies","volume":"81","author":"Rebollo","year":"2003","journal-title":"Immunol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201848075","article-title":"Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1\/NK cell transdifferentiation","volume":"49","author":"Mazzurana","year":"2019","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem Soc Rev"},{"key":"B30","first-page":"59","article-title":"Analysis of Ikaros family splicing variants in human hematopoietic lineages","volume":"34","author":"Matuli\u0107","year":"2010","journal-title":"Coll Antropol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.21037\/atm.2016.09.29","article-title":"Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia","volume":"4","author":"Mitchell","year":"2016","journal-title":"Ann Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e82411","DOI":"10.1371\/journal.pone.0082411","article-title":"The combined expression patterns of Ikaros isoforms characterize different hematological tumor subtypes","volume":"8","author":"Orozco","year":"2013","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113191","article-title":"The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia","volume":"111","author":"Duhamel","year":"2008","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006334","article-title":"Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma","volume":"137","author":"Li","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2174\/138920106779116847","article-title":"Immunomodulatory drugs as a therapy for multiple myeloma","volume":"7","author":"De Raeve","year":"2006","journal-title":"Curr Pharm Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200211000-00008","article-title":"Thalidomide and immunomodulatory drugs as cancer therapy","volume":"14","author":"Raje","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/13543784.14.1.45","article-title":"Thalidomide and immunomodulatory drugs in the treatment of cancer","volume":"14","author":"Bamias","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.12.1963","article-title":"Thalidomide-derived immunomodulatory drugs as therapeutic agents","volume":"4","author":"Galustian","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1486356","article-title":"The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma","volume":"7","author":"Awwad","year":"2018","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-016-0354-2","article-title":"High IKZF1\/3 protein expression is a favorable prognostic factor for survival of relapsed\/refractory multiple myeloma patients treated with lenalidomide","volume":"9","author":"Pourabdollah","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.38","article-title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","volume":"5","author":"Hideshima","year":"2015","journal-title":"Blood Cancer J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.749235","article-title":"Novel immunomodulatory compounds in multiple myeloma","volume":"22","author":"Saini","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"B50","article-title":"Immunomodulatory drugs (IMiDs)","volume":"72","author":"Oshima","year":"2014","journal-title":"Nihon Rinsho"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1450-z","article-title":"The molecular mechanism of thalidomide analogs in hematologic Malignancies","volume":"94","author":"Lindner","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-LB007","article-title":"Abstract LB007: CFT7455: A novel, IKZF1\/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models","volume":"81","author":"Henderson","year":"2021","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v12i15","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.35.22254","article-title":"Molecular cloning of a novel member of the eukaryotic polypeptide chain-releasing factors (eRF). Its identification as eRF3 interacting with eRF1","volume":"273","author":"Hoshino","year":"1998","journal-title":"J Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00035-07","article-title":"Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway","volume":"27","author":"Chauvin","year":"2007","journal-title":"Mol Cell Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cm.10040","article-title":"Yeast polypeptide chain release factors eRF1 and eRF3 are involved in cytoskeleton organization and cell cycle regulation","volume":"52","author":"Valouev","year":"2002","journal-title":"Cell Motil Cytoskeleton"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303179200","article-title":"The polypeptide chain-releasing factor GSPT1\/eRF3 is proteolytically processed into an IAP-binding protein","volume":"278","author":"Hegde","year":"2003","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210740","article-title":"G1 to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1","volume":"27","author":"Lee","year":"2008","journal-title":"Oncogene"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2004.021774","article-title":"Differential expression of the eukaryotic release factor 3 (eRF3\/GSPT1) according to gastric cancer histological types","volume":"58","author":"Malta-Vacas","year":"2005","journal-title":"J Clin Pathol"},{"key":"B60","article-title":"eRF3a\/GSPT1 12-GGC allele increases the susceptibility for breast cancer development","volume":"21","author":"Malta-Vacas","year":"2009","journal-title":"Oncol Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-022-2665-6","article-title":"GSPT1 functions as a tumor promoter in human liver cancer","volume":"43","author":"Xi","year":"2023","journal-title":"Curr Med Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1871529X18666180522073855","article-title":"Treatment of lymphoid and myeloid Malignancies by immunomodulatory drugs","volume":"19","author":"Fuchs","year":"2019","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: A cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J Med Chem"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14952","article-title":"Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis","volume":"8","author":"Nicol\u00e8","year":"2017","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0115-6","article-title":"SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis","volume":"6","author":"Yang","year":"2018","journal-title":"biomark Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2014.11.037","article-title":"SALL4: an emerging cancer biomarker and target","volume":"357","author":"Zhang","year":"2015","journal-title":"Cancer Lett"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13370","article-title":"SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features","volume":"17","author":"Vienot","year":"2023","journal-title":"Mol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"17131","DOI":"10.1038\/s41598-018-35457-6","article-title":"Understanding the thalidomide chirality in biological processes by the self-disproportionation of enantiomers","volume":"8","author":"Tokunaga","year":"2018","journal-title":"Sci Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1211\/0022357001774660","article-title":"Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man","volume":"52","author":"Eriksson","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1021\/ac0203138","article-title":"In vitro biotransformation of (R)- and (S)-thalidomide: application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites","volume":"74","author":"Meyring","year":"2002","journal-title":"Anal Chem"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200351","article-title":"s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line","volume":"5","author":"Liu","year":"2004","journal-title":"Hematol J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"B75","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/s41467-020-18488-4","article-title":"Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide","volume":"11","author":"Furihata","year":"2020","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05333-5","article-title":"The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron","volume":"610","author":"Ichikawa","year":"2022","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.14735\/amko2020260","article-title":"Th e role of CDK12 in tumor bio logy","volume":"33","author":"Dzimkov\u00e1","year":"2020","journal-title":"Klin Onkol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: an emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J Clin Pathol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"105030","DOI":"10.1016\/j.isci.2022.105030","article-title":"CDK12 regulates co-transcriptional splicing and RNA turnover in human cells","volume":"25","author":"Magnuson","year":"2022","journal-title":"iScience"},{"key":"B80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13008-017-0033-x","article-title":"The emerging roles of CDK12 in tumorigenesis","volume":"12","author":"Paculov\u00e1","year":"2017","journal-title":"Cell Div"},{"key":"B81","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-020-00169-2","article-title":"Lack of evidence for CDK12 as an ovarian cancer predisposing gene","volume":"19","author":"Eeckhoutte","year":"2020","journal-title":"Fam Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.903536","article-title":"Stable CDK12 knock-out ovarian cancer cells do not show increased sensitivity to cisplatin and PARP inhibitor treatment","volume":"12","author":"Chil\u00e0","year":"2022","journal-title":"Front Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.007","article-title":"CDK12 gene alterations in prostate cancer: present, but clinically actionable","volume":"78","author":"Marciscano","year":"2020","journal-title":"Eur Urol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3460","article-title":"High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines","volume":"34","author":"Yu","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41589-019-0378-3","article-title":"Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15","volume":"16","author":"Faust","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2374-x","article-title":"The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K","volume":"585","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.3390\/ijms21239026","article-title":"Targeting casein kinase 1 (CK1) in hematological cancers","volume":"21","author":"Janovsk\u00e1","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ccell.2023.02.010","article-title":"Dual IKZF2 and CK1\u03b1 degrader targets acute myeloid leukemia cells","volume":"41","author":"Park","year":"2023","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3390\/ijms22073716","article-title":"Targeting protein kinases in blood cancer: focusing on CK1\u03b1 and CK2","volume":"22","author":"Spinello","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01307-14","article-title":"HSP105 recruits protein phosphatase 2A to dephosphorylate \u03b2-catenin","volume":"35","author":"Yu","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104410","article-title":"MDMX inhibits casein kinase 1\u03b1 activity and stimulates Wnt signaling","volume":"39","author":"Huang","year":"2020","journal-title":"EMBO J"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.16.7277","article-title":"AXIN2 polymorphisms, the \u03b2-catenin destruction complex expression profile and breast cancer susceptibility","volume":"16","author":"Aristizabal-Pachon","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01832","article-title":"Development of PDE6D and CK1\u03b1 Degraders through chemical derivatization of FPFT-2216","volume":"65","author":"Teng","year":"2022","journal-title":"J Med Chem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.c.6672895.v2","article-title":"Overlaid transcriptome and proteome analyses identify mitotic kinesins as important targets of arylsulfonamide-mediated RBM39 degradation","volume":"21","author":"Coomar","year":"2023","journal-title":"Mol Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.664417","article-title":"RBM39 alters phosphorylation of c-jun and binds to viral RNA to promote PRRSV proliferation","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646523","article-title":"Systematic pan-cancer analysis identifies TREM2 as an immunological and prognostic biomarker","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","article-title":"Arginine reprograms metabolism in liver cancer via RBM39","volume":"186","author":"Mossmann","year":"2023","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj5405","article-title":"Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models","volume":"7","author":"Singh","year":"2021","journal-title":"Sci Adv"},{"key":"B106","doi-asserted-by":"publisher","first-page":"113307","DOI":"10.1016\/j.celrep.2023.113307","article-title":"Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex","volume":"16","author":"Bussiere","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.str.2019.10.005","article-title":"Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820","volume":"27","author":"Du","year":"2019","journal-title":"Structure"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid Malignancies: a phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.009618","article-title":"SIAH1 ubiquitin ligase mediates ubiquitination and degradation of Akt3 in neural development","volume":"294","author":"Ko","year":"2019","journal-title":"J Biol Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1420782","article-title":"BCL6 as a therapeutic target for lymphoma","volume":"22","author":"Leeman-Neill","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08420.x","article-title":"The role of BCL6 in lymphomas and routes to therapy","volume":"152","author":"Wagner","year":"2011","journal-title":"Br J Haematol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0082","article-title":"Targeting BCL6 in gastrointestinal stromal tumor promotes p53-mediated apoptosis to enhance the antitumor activity of imatinib","volume":"83","author":"Zeng","year":"2023","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"100193","DOI":"10.1016\/j.crmeth.2022.100193","article-title":"BTB(BCL6) dimers as building blocks for reversible drug-induced protein oligomerization","volume":"2","author":"Nitsch","year":"2022","journal-title":"Cell Rep Methods"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1107\/S2052252520015754","article-title":"Functionalization of the BCL6 BTB domain into a noncovalent crystallization chaperone","volume":"8","author":"Zacharchenko","year":"2021","journal-title":"IUCrJ"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2925-1","article-title":"Small-molecule-induced polymerization triggers degradation of BCL6","volume":"588","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41467-019-09358-9","article-title":"Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction","volume":"10","author":"Simonetta","year":"2019","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/cells12081110","article-title":"A new wave of targeting \u2018Undruggable\u2019 Wnt signaling for cancer therapy: challenges and opportunities","volume":"12","author":"Park","year":"2023","journal-title":"Cells"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1182\/blood.V128.22.1591.1591","article-title":"CC-220 is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines","volume":"128","author":"Bjorklund","year":"2016","journal-title":"Blood"},{"key":"B122","article-title":"First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Niels","year":"2020","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2019-124298","article-title":"Translational and clinical evidence of a differentiated profile for the novel CELMoD, iberdomide (CC-220)","volume":"134","author":"Sagar L","year":"2019","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0105","article-title":"Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic Malignancies","volume":"2","author":"Renneville","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B125","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jha2.v3.2","article-title":"Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"3","author":"Nastoupil","year":"2022","journal-title":"EJHaem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1182\/blood-2018-99-114409","article-title":"Avadomide (CC-122), a novel cereblon modulating agent, plus rituximab in patients with relapsed or refractory follicular lymphoma","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-99-111605","article-title":"Eliciting anti-tumor T cell immunity in chronic lymphocytic leukemia (CLL) with PD-L1\/PD-1 blockade is enhanced by avadomide immunotherapy through the triggering of immunogenic interferon signaling","volume":"132","author":"Ioannou","year":"2018","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134949","article-title":"Long-term results from a phase 1b study of avadomide in combination with obinutuzumab in patients with relapsed and\/or refractory B-cell non-hodgkin lymphoma","volume":"136","author":"Michot","year":"2020","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood.V122.21.2905.2905","article-title":"A first in human dose escalation study of CC-122, A first-in-class pleiotropic pathway modulator\u2122 (PPM) compound in subjects with relapsed or refractory solid tumors, multiple myeloma and non-hodgkin\u2019s lymphoma","volume":"122","author":"Rasco","year":"2013","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1158\/1538-7445.AM2022-3932","article-title":"Abstract 3932: Pathway interaction and mechanistic synergy of CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, with enhancer of zeste homolog 2 inhibitors (EZH2is)","volume":"82","author":"Carrancio","year":"2022","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood-2021-148068","article-title":"CC-99282 is a novel cereblon (CRBN) E3 ligase modulator (CELMoD) agent with enhanced tumoricidal activity in preclinical models of lymphoma","volume":"138","author":"Carrancio","year":"2021","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1182\/blood-2023-188771","article-title":"Efficacy and safety of golcadomide, a novel cereblon E3 ligase modulator (CELMoD) agent, combined with rituximab in a phase 1\/2 open-label study of patients with relapsed\/refractory non-hodgkin lymphoma","volume":"142","author":"Julio CC","year":"2023","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.06.004","article-title":"Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia","volume":"22","author":"Jin","year":"2020","journal-title":"Neoplasia"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v124.13","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer-Am Cancer Soc"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood-2023-182369","article-title":"E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid Malignancies: A phase II clinical trial","volume":"142","author":"Jan","year":"2023","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2021-147160","article-title":"Synergistic combination activity of the novel GSPT1 degrader CC-90009 in acute myeloid leukemia models","volume":"138","author":"Pierce","year":"2021","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/molecules27051496","article-title":"Drug design-past, present, future","volume":"27","author":"Doytchinova","year":"2022","journal-title":"Molecules"},{"key":"B139","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-4939-6634-9_5","article-title":"Computer-aided drug design methods","volume":"1520","author":"Yu","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.2c01317","article-title":"Rational chemical design of molecular glue degraders","volume":"9","author":"Toriki","year":"2023","journal-title":"ACS Cent Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.03.064","article-title":"Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib","volume":"172","author":"Poratti","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s11172-022-3659-z","article-title":"PROTAC: targeted drug strategy. Principles and limitations","volume":"71","author":"Koroleva","year":"2022","journal-title":"Russ Chem Bull"},{"key":"B143","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00953","article-title":"New horizons in KRAS-mutant lung cancer: dawn after darkness","volume":"9","author":"Yang","year":"2019","journal-title":"Front Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"B146","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10822-022-00467-0","article-title":"Modeling receptor flexibility in the structure-based design of KRAS(G12C) inhibitors","volume":"36","author":"Zhu","year":"2022","journal-title":"J Comput Aided Mol Des"},{"key":"B147","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.3c00258","article-title":"2\u2019-deoxy guanosine nucleotides alter the biochemical properties of ras","volume":"62","author":"Yun","year":"2023","journal-title":"Biochemistry"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.943184","article-title":"Deuterated drugs: where are we now","volume":"24","author":"Timmins","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3928\/02793695-20150821-55","article-title":"Deuterated drugs","volume":"53","author":"Howland","year":"2015","journal-title":"J Psychosoc Nurs Men"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1378350","article-title":"Deuterated drugs; updates and obviousness analysis","volume":"27","author":"Timmins","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced Malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417832112","article-title":"Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs","volume":"112","author":"Jacques","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.0c00052","article-title":"Deuterium-enabled chiral switching (DECS) yields chirally pure drugs from chemically interconverting racemates","volume":"11","author":"DeWitt","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.14.528208","article-title":"Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders","author":"Li","year":"2023","journal-title":"bioRxiv"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"116904","DOI":"10.1101\/2023.10.07.561308","article-title":"Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues","volume":"279","author":"Hassan","year":"2023","journal-title":"bioRxiv"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41419-022-05505-1","article-title":"Regulation of programmed cell death by Brd4","volume":"13","author":"Hu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202100180","article-title":"BRD4 in physiology and pathology: \u2018\u2018BET\u2019\u2019 on its partners","volume":"43","author":"Liang","year":"2021","journal-title":"Bioessays"},{"key":"B162","doi-asserted-by":"publisher","first-page":"E3993","DOI":"10.1073\/pnas.1700109114","article-title":"Brd4 modulates the innate immune response through Mnk2-eIF4E pathway-dependent translational control of I\u03baB\u03b1","volume":"114","author":"Bao","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B163","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.molcel.2020.04.034","article-title":"Opposing functions of BRD4 isoforms in breast cancer","volume":"78","author":"Wu","year":"2020","journal-title":"Mol Cell"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1897294","DOI":"10.1080\/2162402X.2021.1897294","article-title":"Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia","volume":"10","author":"Baraga\u00f1o Raneros","year":"2021","journal-title":"Oncoimmunology"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582955","article-title":"Transcriptome-based co-expression of BRD4 and PD-1\/PD-L1 predicts poor overall survival in patients with acute myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"115926","DOI":"10.1016\/j.ejmech.2023.115926","article-title":"Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC","volume":"263","author":"Chen","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B168","doi-asserted-by":"publisher","first-page":"116031","DOI":"10.1016\/j.ejmech.2023.116031","article-title":"Targeting phosphatases: From molecule design to clinical trials","volume":"264","author":"Guo","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B169","doi-asserted-by":"publisher","first-page":"107772","DOI":"10.1016\/j.bioorg.2024.107772","article-title":"Development of natural product-based targeted protein degraders as anticancer agents","volume":"153","author":"Chen","year":"2024","journal-title":"Bioorg Chem"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.4c00286","article-title":"DCAF16-based covalent handle for the rational design of monovalent degraders","volume":"10","author":"Lim","year":"2024","journal-title":"ACS Cent Sci"},{"key":"B171","doi-asserted-by":"publisher","first-page":"104353","DOI":"10.1016\/j.ebiom.2022.104353","article-title":"Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy","volume":"86","author":"Liu","year":"2022","journal-title":"EBioMedicine"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-21-LBA002","article-title":"Abstract LBA002: Targeting GSPT1 by a novel cereblon E3 ligase modulator for the treatment of Acute Lymphoblastic Leukemia","volume":"20","author":"Keramatnia","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB161","article-title":"Abstract LB161: Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)","volume":"84","author":"Lin","year":"2024","journal-title":"Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1042\/BST20230836","article-title":"Lessons from natural molecular glue degraders","volume":"52","author":"Cao","year":"2024","journal-title":"Biochem Soc T"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1512666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T08:19:30Z","timestamp":1735892370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1512666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":174,"alternative-id":["10.3389\/fonc.2024.1512666"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1512666","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"article-number":"1512666"}}